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Challenges in the design, planning and
implementation of trials evaluating group
interventions
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Abstract
Background: Group interventions are interventions delivered to groups of people rather than to individuals and
are used in healthcare for mental health recovery, behaviour change, peer support, self-management and/or health
education. Evaluating group interventions in randomised controlled trials (RCTs) presents trialists with a set of
practical problems, which are not present in RCTs of one-to-one interventions and which may not be immediately
obvious.
Methods: Case-based approach summarising Sheffield trials unit’s experience in the design and implementation of
five group interventions. We reviewed participant recruitment and attrition, facilitator training and attrition,
attendance at the group sessions, group size and fidelity aspects across five RCTs.
Results: Median recruitment across the five trials was 3.2 (range 1.7–21.0) participants per site per month. Group
intervention trials involve a delay in starting the intervention for some participants, until sufficient numbers are
available to start a group. There was no evidence that the timing of consent, relative to randomisation, affected
post-randomisation attrition which was a matter of concern for all trial teams. Group facilitator attrition was
common in studies where facilitators were employed by the health system rather than the by the grant holder and
led to the early closure of one trial; research sites responded by training ‘back-up’ and new facilitators. Trials
specified that participants had to attend a median of 62.5% (range 16.7%–80%) of sessions, in order to receive a
‘therapeutic dose’; a median of 76.7% (range 42.9%–97.8%) received a therapeutic dose. Across the five trials, 75.3%
of all sessions went ahead without the pre-specified ideal group size. A variety of methods were used to assess the
fidelity of group interventions at a group and individual level across the five trials.
Conclusion: This is the first paper to provide an empirical basis for planning group intervention trials. Investigators
should expect delays/difficulties in recruiting groups of the optimal size, plan for both facilitator and participant
attrition, and consider how group attendance and group size affects treatment fidelity.
Trial registration: ISRCTN17993825 registered on 11/10/2016, ISRCTN28645428 registered on 11/04/2012,
ISRCTN61215213 registered on 11/05/2011, ISRCTN67209155 registered on 22/03/2012, ISRCTN19447796 registered
on 20/03/2014.
Keywords: Group interventions, Therapy groups, Treatment fidelity, Implementation, Intervention design, Clinical
trials
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Included trials
JtD [1] Journeying through Dementia.
LM [2] Lifestyle Matters.
PLINY [3] Putting Life IN Years.
REPOSE [4] Relative Effectiveness of Pumps Over Struc-
tured Education.
STEPWISE [5] STructured lifestyle Education for People
WIth SchizophrEnia.
Background
Group interventions in healthcare
Group interventions are used as an alternative, or in
addition to, interventions delivered to individuals in health-
care [6, 7] and involve an intervention delivered to small
groups of people by one or more group leaders rather than
to individuals; this includes activity, support, problem solv-
ing/educational and psychodynamic groups, but does not
includes task or work groups or large education groups [8].
Originally focusing on mental health recovery [6], they now
often also focus on behaviour change, peer support, self-
management and/or health education [7].
Group interventions can present opportunities for costs
savings by treating more than one person at the same
time. In addition, advocates of group interventions have
proposed mechanisms of action that are important for be-
haviour change that arise from being in a group that are
not present in individual therapies, such as inter-personal
change processes, universalisation, social comparison, so-
cial learning and modelling [6, 7, 9, 10]. The role of group
process and dynamics in these mechanisms is contested,
with some believing that these mechanisms of action can
be triggered by individual–therapist interaction [11] and
others proposing that the group aspect is an essential part
of the intervention [12].
Mixed evidence exists for the effectiveness of group in-
terventions. Group interventions improve health out-
comes compared to individual therapy in smoking
cessation [13], breastfeeding [14] and weight manage-
ment [15, 16]; compared to usual care or no intervention
in diabetes [17]; and, are equally effective as individual
therapy in obsessive-compulsive disorder [18].
Clinically effective group interventions do not always
lead to anticipated cost savings compared to individual
treatments, with trade-offs between numbers of patients
treated and the duration or quality of the programmes
[19, 20]. Compared with an individual modality, cogni-
tive behavioural therapy for insomnia [21] and weight
management [15] groups were found to be cost-
effective, whereas smoking cessation groups were not
[13]. Particularly in mental health, there is some concern
that the cost-effectiveness of group interventions com-
pares poorly with one-to-one therapy [22–26]. It is also
said that certain populations may not be suited to group
therapy, including those with communication problems,
disruptive behaviour or co-morbidities that make it hard
to relate to other group members [25].
Group interventions in healthcare tend to be small
groups which involve interaction between members [8].
Small groups are said to move through five stages: the es-
tablishment of ground rules; conflict; cohesion; structure
supportive of task performance; and, termination [7, 27,
28]. This staged development is sometimes used as an ar-
gument for closing group membership after initial ses-
sions, notwithstanding member attrition, which is
common [29]. Optimal group size for group interventions
is said to depend on the type and duration of therapy, as
well as the target population. There is consensus that ideal
group size is 7–8 members, with a range of 5–10 members
[6, 30–33]. Groups with five or more members allow the
formation of meaningful relationships [34] and cohesive
group functioning [6]. Although some maintain that
therapeutic benefit can be derived in groups with < 5
members [35, 36], there is evidence that with < 5 mem-
bers, interaction, group identity, attendance and group
image is poor [6, 37]. Upper limits to group size may de-
pend on how many people a therapist can practically man-
age [38] but it has been found that fewer verbal
interrelationships occur [33] in groups with > 8 members,
and social fission [39] and conflict [40] are more common
in larger groups.
Evaluation of group interventions
In addition to well-documented statistical concerns around
therapist effects and clustering [41], a number of approaches
to evaluating group interventions have been proposed.
Recognising that the design, evaluation and reporting of
group interventions require additional information to that
which is routinely collated for individual interventions, Hod-
dinott and colleagues developed a framework [19] to supple-
ment the Medical Research Council (MRC) guidance on
complex interventions [42]. For instance, in addition to the
intervention content and theory, which would be the same
in one-to-one delivery, documentation of group membership
and maintenance processes (planning, setting up, organising
and sustaining the group), as well as well as the leader/mem-
ber attributes are pivotal to understanding how the interven-
tion works. Borek and colleagues developed a checklist for
the reporting of group-based behaviour change interventions
and a framework detailing the mechanisms of action for
group interventions, which helps researchers describe inter-
vention design and content, participants and facilitators, and
to determine the mechanisms of action present in group in-
terventions [10, 43].
This paper is intended as a supplement to these develop-
ments and outlines practical challenges to the implementa-
tion of group-based therapies in randomised controlled
trials (RCTs). The data provide a ‘reference-class’ – data
from past, similar projects which can be used for
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forecasting [44]. Researchers can use reference class data to
plan and manage trials as well as forecast contingencies re-
lated to: participant recruitment, randomisation and attri-
tion; the demand and supply aspects of intervention
delivery; therapeutic dose; group size; and process
evaluation.
The aim of the present paper is to provide practical
guidance to the implementation of group-based inter-
vention randomised trials based on previous experience
of five group intervention trials conducted by the Shef-
field Clinical Trial Research Unit (CTRU).
Objectives
The primary objective is to present reference class data
specific to group intervention trials on participant re-
cruitment and attrition, facilitator training and attrition,
group attendance, therapeutic dose and group size.
The secondary objectives are to provide explanations
and potential solutions for problems observed in group
intervention trials which are substantively different to
those observed in studies of individual-level interventions.
Methods
Case studies
A case-based approached was adopted to present the
challenges of implementing group interventions in five
RCTs [1–5] evaluating group interventions (Table 1)
managed by Sheffield CTRU [45]—a UK Clinical Re-
search Collaboration (UKCRC)-registered clinical trial
unit managing phase III RCTs of a range of interven-
tions across varied research areas. The CTRU has man-
aged a number of evaluations of complex interventions,
including five completed group intervention trials.
Data were collated from trial reports and journal arti-
cles, from the trial data held in Sheffield CTRU and from
the study managers; descriptive statistics are presented.
Of the included trials, one was cluster-randomised
[4] and all others were individually randomised. Life-
style Matters [2] (LM) was a two-centre trial assessing
a psychosocial group intervention to promote healthy
ageing in adults aged ≥ 65 years with reasonable cog-
nition. Putting Life IN Years [3] (PLINY) was a
single-centre RCT that aimed to evaluate a group
telephone-befriending intervention to prevent loneli-
ness in adults aged ≥ 75 years with reasonable cogni-
tion. Relative Effectiveness of Pumps Over Structured
Education [4] (REPOSE) was an eight-centre cluster
RCT assessing an existing group educational course
for use with multiple daily injections compared to the
same intervention adapted for use with a pump for
adults aged ≥ 18 years with type 1 diabetes. The
STructured lifestyle Education for People WIth
SchizophrEnia [5] (STEPWISE) RCT ran in 10 mental
health organisations and evaluated a group structured
weight management lifestyle education intervention in
adults aged ≥ 18 years with schizophrenia, schizoaffec-
tive disorder or first episode psychosis. Journeying
through Dementia [1] (JtD) was a 13-centre RCT
assessing a group intervention designed to support
people in the early stages of dementia to maintain in-
dependence. All trials took place in the UK.
Various methods for recruitment were used in these
trials and some studies used more than one method [1–
3], including: mail-outs via general practitioners (GPs)/
NHS care teams [1–4]; mail-outs to the research cohort
[1, 3]; referrals via NHS care teams [1, 4, 5]; and self-
referral [1, 2].
Individual randomisation was used in four of the trials
[1–3, 5] and cluster randomisation [4] was used in one.
Randomisation was delayed from the point of consent in
two trials [1, 4] to ensure that the groups were filled and
could be run in the time frame required. Follow-up data
collection was anchored to the time of randomisation in
four of the trials [1–3, 5] and to the commencement of
the first group in one trial [4].
All groups ran for more than one session: one
group intervention [4] took place on five consecutive
days, all other included studies had weekly sessions in
the range of 4–16 weeks and all of the studies had
additional sessions to the main group intervention.
All included interventions were face-to-face sessions,
except for one which was a telephone-befriending
group [3]. A variety of people facilitated the group
sessions in the trials such as NHS staff [1, 2, 4, 5]
and volunteers [3]; all received structured training in
the group intervention and collected research data in
relation to the attendance at group sessions. At least
two facilitators delivered all of the face-to-face inter-
ventions and one person delivered the intervention
via telephone in PLINY [3].
All included studies used some aspect of treatment fi-
delity assessment: direct observation [1, 4, 5] or recording
[2, 3] of a session using a checklist; self-report by facilita-
tors using a checklist [1] in addition to observation; and
assessment of facilitator–participant interaction [5]. In
addition, training fidelity was assessed in three trials by
two researchers either by direct observation [1, 2] or using
audio recordings [3] of training sessions.
Many of the elements discussed above are relevant to
RCTs in general and to RCTs of complex interventions
but some need particular consideration in relation to
group interventions. The type and timing of recruitment
and randomisation are particularly important as these will
dictate when the group sessions can be arranged and how
much time there is to train facilitators. Practical arrange-
ments for group sessions will be affected by the popula-
tion [46], group size, type and length of training, the mode
of group delivery and who the facilitator is.
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Table 1 Details of case studies
Study Population
(target)
Group intervention [additional
sessions]
Facilitator (per session) Method and timing of recruitment Type and timing of randomisation Outcome data collection
LM [2] 65+ years
(prevention:
general)
16 × weekly sessions:
2-h face-to-face
occupational therapy
[4 × one-to-one sessions]
Two NHS Band 4 equivalent staff.
Recruited on university contracts
specifically to deliver the
intervention
Training: two- day face-to-face
course
Mail-out via GPs, healthcare referral
and self-referral from study promotion
(including researchers visiting dementia
cafes and other groups)
Individual.
Done by central team
immediately after consent
and baseline data collection
Central research assistants;
blinded outcome assessor;
follow-up anchored to
randomisation
PLINY [3] 75+ years
(prevention:
loneliness)
12 × weekly sessions: 1-h
telephone friendship [6
× one-to-one telephone
calls before group]
One volunteer from a community
organisation.
Training: 4 × 1 h sessions via
telephone
Mail-out via GPs and to research
cohort
Individual.
Done by central team
immediately after consent
and baseline data collection
Central research assistants;
blinded outcome assessor;
follow-up anchored to
randomisation
REPOSE
[4]
18+ years.
Type I diabetes
(therapy: self-care
education)
5 × daily sessions: full-
day face-to-face
Education (total approx. 38 h).
[1 optional × group follow-up
session]
Two diabetes specialist nurses/
dieticians.
Training: five- day observation,
three-day face-to-face workshop, peer-
reviewed delivery of five-day course
and one-day workshop (105 h)
Referral via care team in person or via
mail-out
Cluster by course in pairs.
Delayed randomisation:
after groups were filled,
6 weeks before first course;
baseline taken after randomisation
Facilitator at clinic visits;
unblinded outcome assessor;
follow-up anchored to group
attendance
STEPWISE
[5]
18+ years. First
episode psychosis
+
schizophrenia
(prevention:
cardiovascular)
4 × weekly sessions: 2.5-h
face-to-face.
[3 × quarterly booster
group sessions and fortnightly
1:1 support calls between
booster sessions]
Two NHS staff (mental health staff;
occupation therapists and dieticians).
Training: three-day face-to-face course
plus one-day booster session training
Referral via care team Individual.
Done immediately after consent
and baseline data collection
CMHT staff or research
nurses; blinded outcome assessor; follow-up
anchored
to randomisation
JtD [1] 18+ years.
Dementia
(prevention:
dependency)
12 × weekly sessions: Approx.
2-h face-to-face psychosocial
education
[4 × one-to-one sessions]
Two NHS staff.
Training: two-day face-to-face course,
plus online resources
Mail-out via GPs/care teams, mail-out
to research cohort by research team,
referral via care team, or self-referral
from study promotion (including
researchers visiting dementia cafes
and other groups)
Individual.
Delayed randomisation: after
collection of baseline data < 2
months before intervention
Central and local site
research assistants; blinded
outcome assessor; follow-up
anchored to randomisation
GP general practitioner
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Results
Participant recruitment and attrition
Table 2 shows the number of individuals approached
and recruited for each trial. Four studies recorded data
on the numbers invited to screen for eligibility and the
associated response rate: 4.1% (LM [2]); 2.9% (PLINY
[3]); 69.2% (REPOSE [4]); and 7.1% (JtD [1]). In REPOSE
[4], acute care teams targeted people with type 1 dia-
betes, compared with the other studies in which GPs
sent out mass mail-outs. LM [2], PLINY [3] and STEP-
WISE [5] were also prevention trials rather than treat-
ment trials, which have shown to be harder to recruit to
[47]. The proportion of those screened providing con-
sent is higher for trials using initial GP mass mail-outs
than for other trials; it is lowest in STEPWISE [5], which
recruited participants with schizophrenia which can be a
difficult population to recruit to trials [48].
Setting group dates
The trials had different approaches to setting the days
and times for the group sessions. Due to the interven-
tion being used outside of the trial, REPOSE set the
dates in advance of participant recruitment, patients
knew when the groups were at the time of consent and
the courses were randomised once the required numbers
were met (usually a minimum of five participants per
group). LM [2] set provisional dates or windows for the
group sessions but finalised the times and dates with the
participants once group numbers were met. STEPWISE
[4] asked sites to block book consent visits (where prac-
tical) and to set course dates in advance which delayed
consent for some participants; sites decided how they
would implement this. The purpose was to minimise
post-randomisation attrition, ensure follow-up occurred
after intervention delivery and to optimise group size.
JtD [5] commenced without pre-planning the dates for
the intervention but as the trial progressed, the trial
team advised sites to set the dates before consent and
many did so. Although these dates sometimes changed,
the trial team ensured that any moved dates were on the
same time and day of the week to increase the possibility
of attendance. PLINY [3] did not pre-plan timing for the
groups and relied on the service provider to set the date
once the group had been recruited. As only one trial ex-
plicitly set the dates before randomisation, we cannot
explore the impact of these differences in our data.
Attrition
Attrition of participants between consent and random-
isation occurred where randomisation was delayed, as
can be seen in the data for REPOSE [4] (n = 4) and JtD
[1] (n = 40). Although randomisation was not delayed in
STEPWISE, there is some attrition between consent and
randomisation (n = 9). Reasons for this were withdrawal
of consent (n = 4), mental health deterioration (n = 4)
and surgery (n = 1), which suggests that there was a
delay in randomising after consent [5], though it was not
designed this way. The percentage of those attending at
least one group session appears unaffected by the timing
of randomisation or by when the days and times of the
group sessions were set.
We have found that maintaining contact with partici-
pants between any of these stages can reduce attrition
while they are waiting for randomisation or for group
sessions to be arranged [49, 50]. In LM, once rando-
mised, facilitators contacted the participants allocated to
the intervention arm to introduce themselves and start
discussing possible dates/times for the next group meet-
ing. The participant would then be aware of timings in-
cluding how long it might be to get a group started; they
would also arrange the first one-to-one session with the
participant to start relationship building. The facilitators
Table 2 CONSORT data
Invited to take
part (mail-out only)
Response rate to mail
out (% of sent)
Screened Eligible
(% of screened)
Consented
(% of screened)
Randomised
(% of screened)
Attended at least one
group session (% of
randomised)
Randomisation concurrent with consent
LM [2] 9330 a 385 (4.1) a 313 294 (93.9) 288 (92.0) 288 (92.0) 123/145 (84.8)
PLINY [3] 9579 b 275 (2.9) b 178 159 (89.3) 157 (88.2) 157 (88.2) 21/78 (26.9)
STEPWISE [5] N/A N/A 1223 989 (80.9) 423 (34.6) 414 (33.9) 171/208 (82.2)
Delayed randomisation
REPOSE [4] 1278 885 (69.2) 362 334 (92.3) 321 (88.7) 317 (87.6) 267/317 c (84.2)
JtD [1] 958 a 68 (7.1) a 1183 521 (44.1) 520 (43.9) 480 (40.6) 217/239 (90.8)
GP general practitioner
a Numbers relate to GP mail outs only
b Numbers relate to GP and research cohort mail-out only
c Participants allocated to both the intervention and control arms attended group sessions
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maintained this contact while waiting for the group
intervention to start. Another challenge that arose from
delayed randomisation related to follow-up: when groups
of people were randomised at the same time and follow-
up was anchored to randomisation, all of the group
members needed to be followed up at the same time
point.
Table 3 shows the recruitment rate by site and by
month for each trial; this is a crude estimate as we have
assumed all sites were open for the whole recruitment
period, which is rarely the case. The median (range) re-
cruitment rate for all included studies is 3.2 (1.7–21.0)
participants per site per month.
Participant demand and facilitator supply
With group interventions, the planned (and actual) re-
cruitment rate needs to be linked to the delivery of the
intervention so that enough people are randomised to a
group without having to wait too long to start the sessions
in order to reduce attrition. This should be forecast in the
early stages of RCT design to ensure an accurate schedule
for the whole trial, taking into account facilitator training,
room booking and other practical aspects of delivery.
Training varied in intensity (See Table 1 for details), with
the training for REPOSE [4] being the most intensive al-
though, unlike in other trials, facilitators were trained be-
fore and independently of the research programme.
Facilitator training
Attrition and replacement of trained facilitators should be
anticipated. Apart from LM [2], studies where facilitators
were trained solely for the research had some attrition of fa-
cilitators and both STEPWISE and JtD had to run more
training sessions than had initially been planned for the trial.
Although LM [2] did not experience facilitator attrition, one
of the facilitators had a period of sick leave and their sessions
were covered by the chief investigator and another person
who required facilitator training. Recruitment of facilitators
can also present difficulties. In JtD [1], the facilitators were
supposed to be provided by the trust, but they often filled
these roles with NHS R&D staff as other staff could not be
recruited to fill the roles. PLINY [3] did not manage to re-
cruit the required number of volunteers to deliver the inter-
vention (Table 4).
PLINY case study: facilitator supply did not meet participant
demand
The PLINY [3] trial had to be stopped prematurely as
there were not enough facilitators to deliver the interven-
tion. PLINY [3] and the service providers (facilitators)
planned to have seven groups of at least six participants,
with staggered start dates so that all groups were running
concurrently by week 16. The start of recruitment was de-
layed from May 2012 to June 2012 and an increased mail-
out was required in October 2012 in order to achieve the
recruitment target. This successful recruitment strategy
meant there were randomised participants (demand) that
required group sessions to be delivered (supply); in this
case, supply did not match the demand.
PLINY [3] was particularly vulnerable to poor supply–de-
mand matching. Funding for the training and hosting of fa-
cilitators sat outside of the University research team, as
Table 3 Recruitment rates
Total randomised Total months recruiting Number of recruiting sites Recruitment rate (total
randomised/site/month)
LM [2] 288 8.3 a 2 17.4
PLINY [3] 157 7.5 b 1 21.0
REPOSE [4] 317 16.7 b 8 2.4
STEPWISE [5] 414 12.9 a 10 3.2
JtD [1] 480 21.2 a 13 1.7
Start date of recruitment taken as either: a the date of the first randomised participant; or b the 1st of the month (where the starting month is reported). The end
date is the last randomised participant in all cases
Table 4 Facilitator training and delivery
Total number of
facilitators fully trained
Number of training sessions -
actual (planned)
Number delivering at
least one group session
LM [2] 5 2 (2) 6 a
PLINY [3] 10 3 (6) 3
STEPWISE [5] 44 b 6 (4) 14
JtD [1] 69 c 12 (4) 60
a Includes the Chief Investigator who did not require training as they developed the intervention
b Foundation training and booster training was delivered separately; here we only include those attending both courses
c Supervisors were also trained in the intervention and have not been included in these numbers
Note: REPOSE [4] is not included in this table as the course ran outside of the trial and therefore the facilitators were trained and managed outside of the
research team
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demanded by the excess treatment cost system – a peculiar-
ity of UK NHS R&D funding [51–55]. Notwithstanding con-
tractual obligations to a research project, if a service provider
has other priorities, the research team have little leverage. In
LM [2] and other trials where facilitators were funded
through research grants and employed by the research pro-
ject, we have observed efficient supply–demand profiles, des-
pite the common problems in participant recruitment.
Figure 1 shows the availability of facilitators against the de-
mand for group sessions. Experienced volunteer coordinators
provided induction and supervision, and an experienced ex-
ternal trainer provided formal group facilitation training to
facilitators so that the group intervention could be delivered
to the target number of participants (n= 124). Funding was
secured from a national charity to do this, which meant that
only local branches of their charity could deliver the
intervention, rather than a number of service providers ori-
ginally planned. Recruitment, training and supervision of fa-
cilitators was therefore the community organisation’s
contracted responsibility and they were in close contact with
the trial team and were informed of participant recruitment
numbers during the trial. Out of the 42 volunteers that
expressed an interest in delivering the group intervention, 10
completed the training and only three delivered the group
sessions; the mean time a volunteer stayed with the project
after they had been trained was 62 days (range 12–118).
Therapeutic dose
The ‘therapeutic dose’ necessary for a change to occur in
complex interventions may be related to certain criteria
being delivered rather than the number of sessions
attended [56]. However, a ‘therapeutic dose’ relating to
Fig. 1 Participant demand, supply of facilitators and group delivery graph for PLINY
Table 5 Number of sessions attended and numbers achieving therapeutic dose
Minimum number of sessions
for ‘therapeutic dose’
(or per protocol population)
Median (range)
sessions attended
Number of participants achieving
‘therapeutic dose’ (% of those
receiving any intervention)
Number attending all planned
sessions (% of those receiving
any intervention)
LM [2] 12/16 (75%) 12 (1–16) 71/123 (57.7%) 5/123 (4.1%)
PLINY [3] 9/12 (75%) 11 (2–12) 9/21 (42.9%) 10/21 (47.6%)
REPOSE [4] 4/5 (80%) 5 (1–5) 261/267 (97.8%) 250/267 (93.6%)
STEPWISE [5] 2/7 a (28.6%) Foundation: 3 (0–4)
Booster: 2 (0–3)
161/171 a (94.2%) 47/171 a (27.5%)
JtD [1] 10/16 b (62.5%) 1:1 sessions: 4 (1–4)
Groups: 9 (0–12)
168/217 b (77.4%) 36/217 b (16.6%)
a Foundation and booster sessions included
b Group and 1:1 sessions included
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attendance is often agreed upon in trials to define the
per-protocol population. In our experience, this has been
decided through consensus of the trial management groups
and the trial steering committees for each trial. Table 5
shows that the ‘therapeutic dose’ in our trials was an attend-
ance rate in the range of 28.6%–80% of the planned sessions.
Across five group therapy programmes, the median
percentage of participants receiving a ‘therapeutic dose’
was 76.7% (range 42.9%–97.8%). REPOSE [4], a treat-
ment trial, where the course ran on five consecutive days
was the most successful at achieving the defined thera-
peutic dose (97.8%) and also achieving attendance at all
sessions (93.6%). Participant motivation to attend group
interventions may be related to the motivation to enrol
in research and therefore may be higher for treatment
trials than for prevention trials [47]. However, JtD, a
treatment trial, does not achieve the high ‘therapeutic
doses’ of REPOSE and STEPWISE, and only REPOSE
had > 50% of participants attending all sessions. In
addition, participants usually had to take a week off
work to ensure attendance at all group sessions for RE-
POSE [4]. For groups that ran weekly for several weeks,
availability may have been more difficult and the time in
between sessions may have led to a change in motivation
or willingness to attend. This can be seen in STEPWISE
as total attendance at the group sessions reduced each
week (144 participants attended their week 1 session,
138 participants attended weeks 2 and 3, and 131 partic-
ipants attended week 4). Booster sessions were 4, 7 and
10months after randomisation and had fewer attendees
than the foundation group sessions (100, 89 and 90,
respectively).
Group size
Table 6 presents the ideal and actual group sizes for
each group intervention.
A total of 45 of 840 (5.3%) planned sessions could not go
ahead as only 1 or 0 participants turned up to the session;
therefore, a group session could not be delivered. All
studies have run groups outside of the ideal range identified
for their intervention, with the majority of sessions running
with fewer than the ideal numbers (619/826 sessions,
74.9%); STEPWISE [5] ran some groups with more than
the ideal numbers (3/826 sessions, 0.4%). REPOSE [4]
achieved the ideal group size in 78.3% of cases whereas all
other trials managed to achieve the desired group size in <
60% of sessions (median 33.4%). In addition to being a
treatment trial that ran daily for one week, REPOSE [4] de-
layed randomisation until there were sufficient numbers to
meet the required group size and, in the early stages,
allowed non-participants to join the usual care arm to
maintain group size and dynamics. When one group was
too small in JtD [1], they allowed additional participants to
join the group for the second session so that the ideal group
size was met. All included studies involved the monitoring
of metrics, such as recruitment and attrition, and interven-
tion adherence there was the opportunity to ensure the
ideal group size, for example by combining small groups or
adding new members, but only one trial team opted for the
addition of new members. In our experience, investigators
are often reluctant to add new members to group interven-
tions after initiation as it may affect the group dynamics,
and if the intervention is time-limited, it would mean new
participants do not have the opportunity to receive the
whole course.
Process evaluation
Process evaluations are often conducted in trials of com-
plex interventions in order to find out what (if any) ele-
ments of the intervention are effective, in what
circumstances and to whom [57, 58]. For group inter-
ventions, the process evaluation should determine if and
why people respond differently to the same group ses-
sions. Process evaluation has a number of components:
context; reach; dose delivered; dose received; fidelity; im-
plementation; and recruitment [57]—which can all im-
pact on the effectiveness of the intervention. Four of our
trials [1–3, 5] included a formal process evaluation based
Table 6 Group sizes
Ideal group
size
Mean number of
participants per
group (SD) a
Median number of
participants per
group (IQR) a
Minimum and
maximum group
size a
Number of sessions delivered
with correct group size
(% of number of sessions delivered a)
Number of sessions with
0 or 1 person recorded
(% of planned sessions)
LM [2] 8–16 7.7 (2.42) 7 (6–9) 2–15 80/173 (46.2%) 13/186 (6.9%)
PLINY [3] 6–8 5.1 (1.17) 6 (4–6) 3–6 24/41 (58.5%) 1/42 (2.4%)
REPOSE
[4]
5–8 5.8 (1.38) 6 (5–7) 3–8 36/46 (78.3%) 0/46 (0%)
STEPWISE
[5]
6–8 Foundation: 4.2
(1.69)
4 (3–5) 2–9 25/129 (18.9%) 3/132 (2.3%)
Booster: 3.5 (1.41) 3 (2–4) 2–8 7/75 (7.1%) 23/98 (23.5%)
JtD [1] 8–12 5.3 (1.71) 6 (4–6) 2–9 32/331 (9.7%) 5/336 (1.5%)
a Sessions recorded in the data with 0 or 1 individual attending have not been included here as this does not constitute a group session, number of sessions
where 0 or 1 were recorded are provided in the final column
Biggs et al. Trials          (2020) 21:116 Page 8 of 16
on these fidelity components and also used the MRC
framework on the evaluation of complex interventions
[42]; three of these trials [2, 3, 5] were designed before
the publication of the MRC Process Evaluation Guidance
[58]. All trials collected data on the trial population,
which provides data relating to reach and recruitment
but only three trials used these data a part of a formal
process evaluation. LM found that the intervention was
delivered correctly and was tailored to groups but reach
and recruitment were issues that led to the intervention
not being effective as the participants may not have been
at a stage where the intervention would have helped
them. STEPWISE found reach and recruitment to be ac-
ceptable but fidelity to the intervention was incomplete.
As previously discussed, PLINY [3] experienced issues
with implementation due to facilitator attrition which
relates to reach, dose delivered and dose received, but
the fidelity assessments also identified issues with deliv-
ery and receipt of treatment.
Table 7 details the fidelity strategies and assessments
used in the trials, apart from in relation to design, as all
five trials fully described the interventions in the proto-
col, including the programme theory where applicable.
The programme theory determines the important as-
pects for the process evaluation and, for group interven-
tions, will include group specific processes. All trials
standardised training and intervention materials as a
strategy for training fidelity. All trials assessed fidelity in
relation to treatment using checklists at a group rather
than an individual level using checklists to determine
what was delivered by the facilitator. These assessed the
delivery of the intervention to the whole group and
whether the members took part as intended. The fidelity
checklists often included questions asking if the group
leader was able to facilitate group processes such as peer
exchange, mutual support, group cohesion, group en-
gagement and group goals.
STEPWISE [5] used an observation tool during direct
observation of sessions to assess a group specific
process—the interaction between the facilitator and the
participants, as this was considered a key component of
the group intervention. The checklists used for assessing
treatment delivery fidelity for STEPWISE [5] also in-
cluded elements relating to the receipt of the interven-
tion and enactment of skills while in the group session.
All included trials conducted some qualitative re-
search that covered acceptability or satisfaction for a
subset of participants and facilitators; STEPWISE [5]
also explored implementation using Normalisation
Process Theory (NPT) [59] and interviewed the inter-
vention developers to inform the process evaluation. In
addition, all studies used the qualitative research under-
taken with participants to assess fidelity in terms of the
receipt of the intervention, with LM [2], REPOSE [4],
STEPWISE [5] and JtD [1] also looking at enactment of
skills.
Clustering concerns
Couple recruitment
LM [2] recruited 18 couples which presented the study
team with issues that are not well documented in the lit-
erature, though statistical concerns regarding the analysis
of group interventions, or clusters, are well documented
[60–64]. In LM [2], couples were randomised as a pair so
that they received the same allocation, which reduces the
risk of contamination between arms, and is often pre-
ferred by paired participants [65]. If couples (or twins) are
randomised to the same group, outcomes are likely to be
more similar in this group than in others. To account for
this, the statistical analysis of the LM outcome data used a
multi-level mixed effects model [2]. JtD also allowed the
inclusion of couples and stated at the outset that they
would be randomised together as in LM; one couple was
recruited. The statistical analysis plan detailed the use of a
multi-level mixed effects model if > 10 couples had been
recruited, with the intervention as a top-level random ef-
fect and couples/singles as a lower-level random effect.
There are two other potential solutions to this: average
the couple’s continuous outcomes and treat them as one
individual; or only collect outcome data on one member,
the index member. When averaging outcomes across a
couple results in a hybrid rather than an individual, the
data are difficult to fit in the baseline characteristics table
and categorical outcomes cannot be handled in the same
way. Indexing is a simple solution, though decisions re-
garding how to choose the index member from the couple
are required and it is wasteful discounting one partici-
pant’s data when they are included in the research, espe-
cially when recruitment to trials can be difficult.
More than one facilitator
More than one facilitator may run a group during the
intervention period. Two facilitators delivered LM, RE-
POSE, STEPWISE and JtD intervention sessions as
standard. Additionally, if the group interventions run for
more than one session, the facilitator may (and often
did) change during the course for a number of reasons.
For example, in LM, one facilitator was sick for a
number of weeks and two other facilitators covered the
group sessions that they missed: four different people (in
three combinations of pairs) delivered the intervention
to one group of participants. This creates a problem for
those wishing to conduct fidelity analyses. In principle,
the effect of therapists can be modelled either by using
the therapist identifier as a fixed effect in the statistical
model or by characterising them in terms of experience.
However, where there is more than one therapist per
group, it is difficult to identify a therapist effect on an
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Table 7 Fidelity elements included in the trials [59]
Training Delivery of treatment Receipt of treatment Enactment of skills Findings a
LM [2] Standardised training and materials;
direct observation of training, checklist
used by two researchers
Visual recording of a purposive sample of
sessions; assessed by two people using
delivery checklist; facilitator supervision;
attendance registers
Assessed through qualitative
research with a subset of
participants at 6 months after
randomisation; attendance
registers
Assessed through
qualitative research with
a subset of participants
at 6 and 24 months after
randomisation
Reported as categorical for fidelity:
Satisfactory (based on a continuous
fidelity score of 61%–70%) in 7/8
recordings for both participant and
facilitator performance
PLINY [3] Standardised training and materials;
audio recording of purposive sample
of training sessions; checklist used by
two researchers; checklist for facilitator
skill acquisition
Audio recording of sample of groups at
three timepoints; assessed by two people
using delivery checklist; facilitator supervision;
attendance registers
Checklist for treatment included
elements of receipt and assessed
through qualitative research with
a subset of participants;
attendance registers
As for receipt, as
enactment of skills
should have taken place
in the group sessions in
this intervention
Reported percentage scores for
fidelity: Training scores were high
but overall fidelity scores for
facilitators were low
REPOSE
[4]
Standardised training and materials Direct observation of particular sessions in
intervention arm; existing quality assurance
for standard DAFNE course; facilitator
supervision + feedback from fidelity
assessment; attendance registers
Assessed through qualitative
research with a subset of
participants immediately after
intervention; attendance registers
Assessed through
qualitative research with
a subset of participants
at 6 months after
intervention
Achievement of essential outcomes
assessed as: Yes, Partial (with a
percentage) or Not Observed; appear
to be delivered as planned; fed back
to facilitators
STEPWISE
[5]
Standardised training and materials Direct observation of a sample of 30 sessions
in 10 sites using a checklist and an
interaction observation tool; also explored in
qualitative interviews with a subset of
participants, facilitators and intervention
developers; facilitator supervision; attendance
registers
Assessed through qualitative interviews with a subset of
participants and facilitators; checklist for session included
elements of receipt and enactment; attendance registers
Reported percent of facilitator talk
time and the percent of time in
positive and negative behaviours; poor
intervention fidelity reported
JtD [1] Standardised training and materials;
direct observation of training, checklist
used by two researchers; checklist for
facilitator skill acquisition
Direct observation of two sessions of four
groups at four sites; checklist used by two
independent observers; self-report checklist
by facilitator at each session; facilitator super-
vision and supervision checklists; attendance
registers
Assessed through qualitative
interviews with a subset of
participants; attendance registers
Assessed through
qualitative interviews
with a subset of
participants
The fidelity data have not yet been
analysed or interpreted
a Findings relating to attendance (delivery and receipt elements) are reported in Tables 5 and 6
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individual participant’s outcome – analysts soon require
degrees of freedom which are unavailable from trial sam-
ples. Instead, it is common to analyse group interven-
tions using a random effect; doing so does not attempt
to explain variation in terms of the participants or the
facilitators but rather say that outcomes for individuals
in the same group are more similar than for individuals
across two different groups. This allows each group (ra-
ther than each facilitator) to have different outcomes
and acknowledges that facilitators are only one part of
this [66]. Nevertheless, the theory of a group effect was
not borne out in REPOSE and STEPWISE where the
clustering effects were zero.
Discussion
Principal findings
Participant recruitment and attrition
We have presented the recruitment and attrition rates
for our group intervention trials so that future investiga-
tors can use these for forecasting recruitment for group
intervention trials for similar populations and settings.
Recruitment to our group intervention trials was higher
than has been reported in individually randomised trials
(which may include group interventions) [67], suggesting
that recruitment to group intervention trials may be eas-
ier than recruitment to individual intervention trials,
though comparing recruitment rates across a range of
interventions, disease areas and settings is problematic
as there are a multitude of factors involved.
A key factor in designing RCTs assessing group inter-
ventions is the timing of the various steps required before
a participant attends a group session – consent, random-
isation and setting dates for the group sessions. There is
insufficient evidence from our trials to show that the
timing of consent and randomisation affects the rate of at-
trition before initiation of groups. Attrition before ran-
domisation may be preferred to post-randomisation
attrition to maintain statistical power. Delaying random-
isation could reduce the time between randomisation and
group initiation, therefore reducing the waiting time for
participants and the potential for post-randomisation at-
trition. However, the two trials that delayed randomisation
experienced a similar level of post-randomisation attrition
to two of the trials that randomised at the point of con-
sent. Attrition also appears unaffected by the point at
which the dates for the group sessions are decided, but
the timing of setting dates may affect recruitment and at-
trition in a way not captured by our data. Knowing the
dates (or even just the day and time) of the groups before
consent could, in theory, reduce recruitment as potential
participants may not be able to attend on those dates, but
it should in turn reduce attrition after consent as they
have already checked their availability.
Delaying randomisation also has implications for cap-
acity of those collecting data as participants may need to
be follow-up at the same time.
Facilitator training and attrition
Sustaining delivery of group sessions is affected by facilita-
tor attrition and the ability to train new facilitators. We
have provided evidence to show that facilitator attrition
should be expected for group intervention trials and train-
ing sessions should be planned accordingly, throughout
the trial. As there are often two facilitators required to de-
liver group interventions, this may have a bigger impact
on group intervention trials than trials assessing individual
interventions which usually only have one person deliver-
ing the session. Centres attempted to address facilitator at-
trition and absence, either by having ‘back-up’ facilitators
or by training new facilitators. In one case where this was
not possible [3, 68], the trial was stopped prematurely.
When designing RCTs of group interventions, consider-
ation should be given to who will be delivering it and how
this is funded as this may impact on implementation.
Therapeutic dose
Across five trials participants had to attend a median of
62.5% (range 16.7%–80%) sessions, in order to have received
a ‘therapeutic dose’; a median of 76.7% (range 42.9%–97.8%)
of participants received the ‘therapeutic dose’. These figures
can be used to help future investigators determine a per-
protocol population for group intervention trials, bearing in
mind that this will vary according to the intervention
depending on the mechanisms of action. In general, setting
the bar low for a therapeutic dose meant that more people
received it, though this may influence the effectiveness of the
intervention, and should be considered in any process
evaluation and analysis.
Group size
All studies ran group sessions that were outside the pre-
specified ideal size range: across five group interventions,
74.9% of all sessions ran with fewer than ideal numbers
and 0.4% ran with more than the ideal numbers. The
group intervention aimed at treatment that ran daily for
a week was the most successful at meeting the ideal
group size; the trial with intervention sessions that were
further from the point of randomisation, and further
apart in time (booster sessions in STEPWISE), was the
least successful and had the lowest average group size.
This suggests that the duration of the intervention may
be important in maintaining group membership and
how many individuals attend all sessions or the number
of sessions defining the per-protocol population.
Two trials responded to small group size; one by adding
new participants in the second week and one by allowing
non-participants to join the groups, which along with
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Table 8 Challenges and potential solutions to the implementation of group interventions
Challenges in group intervention implementation Potential solutions
Participant recruitment: A number of participants (likely to be a minimum of 8 in each arm to
allow for drop out) need to be recruited before a group intervention can commence
Participant recruitment rates can be affected by the relative timing of screening, randomisation
and initiation of group, but there is no clear signal as to the best strategy
Recruitment projection and the timing of intervention delivery need to be considered together at
the design stage. Those planning group intervention trials should consider demand-forecasting
procedures, like those used in clinical settings characterised by surges and slumps and should aim
for the maximum group number before commencing the group sessions to allow for attrition.
Consider the pros and cons of randomising patients closer to consent (potentially better for
accrual rates) or to group initiation (potentially better for retention rates)
Participant attrition: Attrition may be greater where individuals are required to wait longer before
starting the group sessions (due to the requirement of recruiting enough people per group)
Delaying randomisation until there are enough recruited participants to run the group may lead
to attrition between consent and randomisation but reduce post-randomisation, pre-intervention
attrition, which is important to maintain statistical power
Maintaining contact with participants before randomisation and the setting up of group sessions
may help to reduce pre-randomisation attrition
If randomising a number of participants at the same time, trialists should consider and plan for the
impact on the follow-up data collection, these participants will need to be followed-up at the
same time
Setting group dates: Deciding when to set the group sessions can be challenging. Day/dates can
be set before recruitment or once all participants needed for a group session are recruited
Our data did not suggest that either method is superior
Those planning group intervention trials should plan groups around the recruitment projection
and allow for some flexibility if recruitment does not go as planned
Facilitator training and attrition: Two facilitators are often needed to run group sessions. Recruiting
facilitators can be challenging
Group facilitators will be lost over the course of the intervention delivery – our data show 70%
attrition of trained facilitators in one trial
Allow enough time to recruit and train facilitators prior to the start of recruitment
Plan to train replacement facilitators at each site, and/or plan for training sessions throughout the
project to account for facilitator attrition or re-training facilitators
Group dynamics are important to group interventions; any change in facilitator should be
recorded and investigated as part of the process evaluation and through multi-level modelling for
analysis where appropriate
Therapeutic dose: This can be difficult to determine for complex interventions but is required for a
per-protocol analysis. This may be more difficult for group interventions, as there is less control
over what people are exposed to than in one-to-one sessions
In our experience, investigators define a therapeutic dose by a threshold number of sessions
attended
Defining the per-protocol population should be undertaken by expert consensus, with oversight
from the project steering committee. Time should be reserved for this purpose during protocol
development
For group interventions, ‘therapeutic dose’ may relate to certain intervention criteria being
delivered rather than the number of sessions attended and this should be investigated as part of
the process evaluation
Group size: An ideal group size will be applicable to the intervention but may be difficult to
achieve for all group sessions. Groups may have to run with fewer participants than the ideal.
There may be reluctance to amend the group membership (e.g. by adding new participants) once
running due to the impact of group dynamics
The impact of group size on the effectiveness of the intervention and must be considered in
fidelity assessments and on outcomes
Protocol development should include discussions about what happens in the event of small
groups and should specify if any number of participants is too few for intervention delivery. Can
groups be combined or can new participants or non-participants be added? Consider whether the
group size or the maintenance of group dynamics is more important to the intervention
Process evaluation: Assumes interventions work at an individual level meaning some constructs
may need adapting for assessing group interventions
Recruitment and ‘dose delivered’ can be assessed at the group level whereas ‘dose received’ can
be assessed at the individual level; fidelity can be assessed at the group (delivery) or individual
level (receipt and enactment of skills)
Process evaluations should include components of the intervention specific to group processes,
such as facilitation techniques, group dynamics and development and inter-personal change
processes
Clustering issues: Couples recruited to trials and participants that receive the same intervention
from the same facilitators are likely to have more similar outcomes than if this was not the case.
RCTs may not be powered to use multi-level modelling
This needs to be accounted for in the sample size calculation and made clear when interpreting
the findings
RCT randomised controlled trial
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merging small groups, are potential solutions to less than
ideal group sizes but usage will depend on the intervention
and what elements of group processes are important [7].
Process evaluation
By nature, group interventions are complex interven-
tions and participants can have different outcomes even
if they have received the same intervention delivered by
the same facilitator. Process evaluations should be con-
ducted alongside group intervention evaluations to pro-
vide information on when the intervention might be
successful or when it might fail. Aspects of process
evaluation can be assessed at a group or individual level,
though guidance assumes interventions work on an indi-
vidual level. At a group level, quantitative process data,
such as non-recruited data and attendance data (recruit-
ment, reach and dose delivered) can be collected, and el-
ements of fidelity, such as treatment receipt and
enactment, can be built into quantitative checklists. On
an individual level, receipt and enactment can be investi-
gated in participants using qualitative methods.
Some group-specific processes may need a specific
group size or for a certain number of sessions to be
attended or for certain criteria to be delivered during the
sessions. The recently published mechanisms of action in
group-based interventions (MAGI) framework [10] may
help investigators to identify the group-specific processes
essential to the success of a group intervention which
should then be used to inform the process evaluation.
Clustering issues
We have highlighted two potential issues relating to
clustering that may arise in the sample size estimation
and the analysis for group interventions: the inclusion of
couples and the delivery of the intervention by multiple
therapists, which should be accounted for in sample size
calculations or in the interpretation of the findings.
Challenges and solutions for group intervention
implementation
Table 8 presents the challenges and potential solutions
to the implementation of group interventions in RCTs.
Strengths and limitations
The data presented here provide a reference class [44, 69]
that researchers can use to plan/manage trials and forecast
contingencies. This is valuable as CONSORT diagrams
tend to under-report activity before randomisation [47].
Using a case-based approach to explore the experiences of
implementing group interventions in trials is appropriate
and provides useful data from a range of trials. However,
the corpus represents one CTRU’s experience and, while
it represents a wide range of clinical and geographic con-
texts, the settings, roles, interactions and relationships
[70] associated with each trial inevitably affect outcomes
in ways not captured by our dataset. For instance, the
group intervention trials in our sample is weighted to-
wards prevention [2, 3, 5] rather than therapy [1, 4], which
are known to have different recruitment dynamics [47],
possibly due to motivation to attend and engage [71–73].
Recommendations
Those planning group intervention trials should consider de-
mand forecasting procedures, as are used in clinical settings
characterised by surges and slumps [74–76]. Anecdotal testi-
mony from site staff and trial managers suggests that main-
taining contact with participants during recruitment and
follow-up stages helps to reduce attrition from research and
intervention protocols [49]. Post-randomisation exclusions
should be avoided [77] but if randomisation is delayed to re-
duce the attrition after randomisation [78], then trialists
should be aware of the possibility of attrition between con-
sent and randomisation.
Thought should be given to selection and justification of
the therapeutic dose and how this may be affected by the
number of sessions and group size. As it is unlikely that
complex interventions are characterised by linear dose-
response patterns [79], trialists should reflect on whether the
idea of a ‘therapeutic dose’, proposed by some process evalu-
ators [57], is a useful one. Those retaining session delivery/
receipt as an index of ‘therapeutic dose’ should consider how
the level at which it is set affects the number of people who
will achieve it; the same will be true for fidelity assessment
based on satisfying a threshold number of criteria. Guidance
on process evaluation [80] currently assumes interventions
work at an individual level so constructs may require adapta-
tion in group intervention trials: recruitment and ‘dose
delivered’ can be assessed at the group level whereas ‘dose
received’ can be assessed at the individual level; fidelity be
assessed at the group (delivery) or individual level (receipt
and enactment of skills). Recently developed checklists and
frameworks [10, 19, 43] for group-based behaviour change
interventions can be used to aid the reporting and
design of these interventions and for identifying the
relevant mechanisms of action, which should inform
the associated process evaluation.
As attrition can affect fidelity, study design should in-
clude courses of action (group cessation, combination of
two groups, membership replenishment, inclusion of
non-research participants) for when, inevitably, group
sizes drop below an acceptable threshold. As the group
context and process are often said to ‘constitute the
treatment intervention’ [12], investigators are often re-
luctant to replenish groups after member attrition, al-
though this is common in many successful ‘open/rolling’
therapy groups [81], including some that have been the
subject of trials [50]. Planning for therapist attrition can
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involve the properly resourced use of contracts, supervi-
sion and the training of back-up therapists [50].
Challenges discussed in this paper will vary depending
on the population and disease area being studied and
the type of group intervention being evaluated and these
may be identified in a pilot or feasibility study imple-
menting the intervention.
Further research
A threat to the implementation of cluster RCTs involving
group interventions, not addressed in this paper, is the
timing of cluster randomisation. To contain costs, investi-
gators must work to reduce the time between ethical ap-
provals and the set-up of participating centres. Research is
needed on how contracting, the allocation of resources,
staffing and training (which are not needed at all sites) can
be expedited to allow rapid site initiation. Poor group
composition due to errors in patient selection can result
in disruption of therapy or participant attrition [82, 83].
Further work is required to understand how investigators
can employ rational methods of participant allocation to
therapy groups [83] in the context of cluster RCTs.
Conclusions
This paper provides a rational basis for planning group
intervention trials, especially how to match the demand of
research participants to the supply of trained group facili-
tators. Investigators need to consider how to time consent
and randomisation to minimise post-randomisation attri-
tion. They should plan for both facilitator and participant
attrition and consider how group attendance and group
size affects treatment fidelity. Further research is needed
on expedited set-up of sites in cluster randomised RCTs
involving group therapies as well as appropriate baseline
group composition and participant replenishment follow-
ing attrition.
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